Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02407028 · ClinicalTrials.gov registry record · Phase 2

Hyperbaric Oxygen Brain Injury Treatment Trial

A Phase 2 study of Traumatic Brain Injury, sponsored by Gaylan Rockswold.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
11
Study locations

NCT02407028: Recruiting Phase 2 study of Traumatic Brain Injury, sponsored by Gaylan Rockswold.

NCT02407028 is a Phase 2 study of Traumatic Brain Injury that is actively recruiting participants, run by Gaylan Rockswold. The registered enrollment target is 200 participants, below the 276-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (28% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02407028, a Phase 2 study of Traumatic Brain Injury, is actively recruiting participants, sponsored by Gaylan Rockswold.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the outcome of severe TBI patients in a subsequent phase III trial.

Conditions Studied

Interventions

  • DRUG Hyperbaric oxygen (1.5 ATA, no NBH)
  • DRUG Hyperbaric oxygen (2.0 ATA, no NBH)
  • DRUG Hyperbaric oxygen (2.5 ATA, no NBH)
  • DRUG Hyperbaric oxygen (1.5 ATA + NBH)
  • DRUG Hyperbaric oxygen (2.0 ATA + NBH)

Study Locations (11)

California

  • UCSD Medical Center - Hillcrest Hospital - San Diego

Florida

  • St. Mary's Medical Center - West Palm Beach

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Kentucky

  • University of Kentucky Hospital - Lexington

Maryland

  • University of Maryland - Baltimore

Michigan

  • Detroit Receiving Hospital - Detroit

Minnesota

  • Hennepin County Hospital - Minneapolis

Nebraska

  • University of Nebraska Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2018-06-25
Est. Completion 2029-06-30
Phase Phase 2
Gaylan Rockswold

1 total trials

What NCT02407028 shows while recruiting

NCT02407028 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 276-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (28% lower).

The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 5 interventions - of which Hyperbaric oxygen (1.5 ATA, no NBH) is the first listed.

NCT02407028 lists 11 locations in 11 states (California, Florida, Iowa).

Frequently Asked Questions

What is clinical trial NCT02407028 about?

NCT02407028 is a clinical study titled "Hyperbaric Oxygen Brain Injury Treatment Trial". The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the outcome of severe TBI patients in a subsequent phase III trial.

What is the current status of trial NCT02407028?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2018-06-25. Estimated completion is 2029-06-30.

What conditions does trial NCT02407028 study?

This clinical trial studies the following conditions: Traumatic Brain Injury.

What interventions are being tested in trial NCT02407028?

The interventions under investigation include: Hyperbaric oxygen (1.5 ATA, no NBH) (DRUG), Hyperbaric oxygen (2.0 ATA, no NBH) (DRUG), Hyperbaric oxygen (2.5 ATA, no NBH) (DRUG), Hyperbaric oxygen (1.5 ATA + NBH) (DRUG), Hyperbaric oxygen (2.0 ATA + NBH) (DRUG).

Who is sponsoring clinical trial NCT02407028?

This trial is sponsored by Gaylan Rockswold, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02407028 being conducted?

This trial has 11 study locations across California, Florida, Iowa, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Traumatic Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02407028's enrollment target sits among peer trials

200 33rd of 171 higher than 137 of 171 other Traumatic Brain Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02407028, the US trial registry maintained by the National Library of Medicine. NCT02407028 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.